Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs CGON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Captures Overall Composite Edge (45.0 HOLD vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars

CGON Overall Winner 6-Pillar Tally: RGNX 4 – 2 CGON Matrix Metrics: RGNX 3 – 5 CGON

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (45.0/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.45 (N/M Forward P/E, -120.4% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin).

  • Growth vs. Quality Trade-Off: CGON earns the overall head-to-head edge with a stronger Unified Composite Score (45.0/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.77β · 86% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs CGON
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.82β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.77β · 86% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25

6-Pillar Scorecard Institutional Category Breakdown (RGNX 4 – 2 CGON)

Columns: Metric · RGNX · CGON
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x N/M
2. Growth & Scale CGON
Revenue Growth (YoY) -69.2% -3.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M $6.2M
Market Cap $500.9M $6.3B
3. Profitability & Quality RGNX
Gross Margin -64.5% N/A
Operating Margin -120.4% -4293.5%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -28.3%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$189M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 349.6% (52nd %ile) 238.6% (85th %ile)
Put/Call OI Skew N/A 0.35x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (3) vs CGON (5)
Institutional Metric RGNX CGON Criterion Row Edge
Market Capitalization
Scale
$500.9M $6.3B Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% -3.7% Higher Growth CGON
Operating Margin (TTM)
Profitability
-120.4% -4293.5% Higher Margin RGNX
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-113.2% -28.3% Higher ROE CGON
52-Week Range Position
Momentum
19% ($5–$16) 84% ($37–$94) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
1.82β · 76% Vol 0.77β · 86% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M $6.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$189M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +34.33 pp
RGNX: +7.58% · CGON: +41.91%
3M Horizon CGON +44.03 pp
RGNX: -32.7% · CGON: +11.33%
6M Horizon CGON +3.11 pp
RGNX: +31.86% · CGON: +34.97%
1Y Horizon CGON +160.93 pp
RGNX: -36.0% · CGON: +124.93%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue CGON Revenue RGNX Op. Margin CGON Op. Margin Margin Leader
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -27180.9% RGNX
FY2024 $80M $0M -280.0% -10067.3% RGNX
FY2025 $170M $0M -94.6% -4722.1% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs CGON Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (45.0/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.45 (N/M Forward P/E, -120.4% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin). Growth vs. Quality Trade-Off: CGON earns the overall head-to-head edge with a stronger Unified Composite Score (45.0/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.77β · 86% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGON leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while CGON shifted N/A. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus CGON (-28.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.